New antibody combo shows promise in early cancer trial

NCT ID NCT05174585

Completed Disease control Sponsor: Jacobio Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested an experimental drug called JAB-BX102, alone or with the immunotherapy pembrolizumab, in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also looking for signs that the tumors shrink. The trial has been completed, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JAB-BX102 (an experimental antibody) and pembrolizumab (a cancer immunotherapy)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early-phase trial with only 21 participants, so results are preliminary. The drug may not shrink tumors or could cause side effects. It is not yet proven to work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China
Huashan Hospital

Shanghai, Shanghai Municipality, 200040, China
Hunan Cancer Hospital

Changsha, Hunan, 410013, China
Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China
The First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui, 233004, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.